Ischemia-reperfusion injury, occurring when blood flow is interrupted and then restored, poses a significant challenge in medical procedures like organ transplantation and during events such as heart attacks and strokes. This injury can lead to complications such as delayed graft function in kidney transplant recipients.

cellvie is developing Therapeutic Mitochondria Transplantation, a method to augment and replace dysfunctional mitochondria within cells, thereby restoring cellular energy metabolism. This approach aims to address ischemia-reperfusion injury, particularly in the context of kidney transplantation, by reducing the incidence of delayed graft function. By reinvigorating the cell's energy production, this technology offers a novel treatment modality for conditions where mitochondrial dysfunction plays a key role. The company's focus extends beyond ischemia-reperfusion injury to explore applications in slowing or reversing degenerative processes associated with aging.

Therapeutic Mitochondria Transplantation technique to augment and replace dysfunctional mitochondria.

Targeted application for ischemia-reperfusion injury arising in heart attacks, stroke, surgical procedures, and organ transplantation.

Focus on reducing delayed graft function in kidney transplant recipients.

Aims to restore cellular energy metabolism by directly addressing mitochondrial function.

The primary target audience includes patients undergoing organ transplantation, particularly kidney transplantation, and individuals at risk of ischemia-reperfusion injury due to heart attacks, strokes, or surgical procedures.